Shilpa Gupta, MD, Cleveland Clinic

Sequencing Considerations in mUC after Frontline IO

August 26th 2020

Metastatic Bladder Cancer: Progression After Maintenance

August 26th 2020

Educating Patients on Maintenance Therapy in mUC

August 26th 2020

Changing the Standard of Care in Metastatic Bladder Cancer

August 26th 2020

Practical Management of AEs in Metastatic Bladder Cancer

August 26th 2020

Safety Data from JAVELIN Bladder 100

August 26th 2020

Increased Survival Outcomes with Switch Maintenance in mUC

August 26th 2020

Switch Maintenance Strategy for Metastatic Bladder Cancer

August 26th 2020

Value of PD-L1 Testing in Metastatic Urothelial Cancer

August 26th 2020

PD-L1 Expression in Metastatic Urothelial Cancer

August 26th 2020

Current Status of Therapy: Metastatic Urothelial Cancer

August 26th 2020

Dr. Gupta on Challenges With Perioperative Immunotherapy in Bladder Cancers

July 8th 2020

Shilpa Gupta, MD, discusses challenges with ​perioperative immunotherapy in bladder cancer.

Dr. Gupta on Neoadjuvant Versus Adjuvant Immunotherapy in Urothelial Carcinoma

June 16th 2020

Shilpa Gupta, MD, discusses the potential utility of neoadjuvant versus adjuvant immunotherapy in urothelial carcinoma.

Dr. Gupta on BLASST-1 Results in Muscle-Invasive Bladder Cancer

February 13th 2020

Shilpa Gupta, MD, medical oncologist, Department of Hematology and Medical Oncology, Cleveland Clinic, discusses the results of the phase II BLASST-1 trial, which is evaluating nivolumab, gemcitabine, and cisplatin in patients with muscle-invasive bladder cancer who are undergoing cystectomy.

Dr. Gupta on Challenges of Identifying Biomarkers in Bladder Cancer

October 15th 2019

Shilpa Gupta, MD, discusses the challenges of identifying predictive biomarkers in bladder cancer.

Dr. Gupta on Enzalutamide/Chemo Combo in Metastatic Bladder Cancer

September 10th 2019

Shilpa Gupta, MD, associate professor of medicine, Hematology/Oncology and Transplantation Division, University of Minnesota, discusses the results of the phase I/Ib trial investigating the use of frontline enzalutamide, gemcitabine and cisplatin in metastatic bladder cancer.

Dr. Gupta Discusses Combination Immunotherapy in RCC

September 10th 2018

Shilpa Gupta, MD, assistant professor of medicine, Hematology/Oncology and Transplantation Division, University of Minnesota, discusses combination immunotherapy in renal cell carcinoma.

Dr. Gupta on Genomic Characterization of MIBC Histology to Predict Response

August 9th 2018

Shilpa Gupta, MD, assistant professor, Hematology Oncology and Transplantation Division, University of Minnesota, discusses genomic characterization of muscle invasive bladder cancer histology to predict therapy response.

Dr. Gupta on Impact of Pembrolizumab Plus Bevacizumab Findings in RCC

July 10th 2018

Shilpa Gupta, MD, assistant professor of medicine, Hematology/Oncology and Transplantation Division, University of Minnesota, discusses the impact of the phase Ib/II results of pembrolizumab (Keytruda) plus bevacizumab (Avastin) in patients with metastatic renal cell carcinoma.

Dr. Gupta on Phase Ib/II Trial of Pembrolizumab With Bevacizumab in RCC

June 14th 2018

Shilpa Gupta, MD, assistant professor of medicine, Hematology/Oncology and Transplantation Division, University of Minnesota, discusses the phase Ib/II studies of pembrolizumab with bevacizumab for the treatment of patients with metastatic renal cell carcinoma.